About this historical patient account: The information below describes reported observations from one case. It does not establish treatment efficacy, safety, a causal relationship or an expected outcome. Outcomes vary, and reported improvement does not demonstrate cure. Do not change prescribed medicines or delay established care based on this account.

Intervention context: This account does not establish that the cell, growth-factor or other biological interventions described are approved or effective for this diagnosis. Some may be investigational. A qualified specialist should explain the current evidence, regulatory status, alternatives, uncertainties and risks before any treatment decision.

Patient Information:

• Name: Mark
• Diagnosis: Diabetes (Type 1)
• Date of Birth (D.O.B): April 26, 2002
• Gender: Male
• Country: Republic of Lithuania

Treatment: Interventional therapy, Biotherapy, Physical Therapy, Traditional Chinese Medicine (TCM) at Beijing Puhua International Hospital

Medical History:
Mark, a 17-year-old male from Lithuania, was admitted to Beijing Puhua International Hospital for diabetes management. He had previously received treatments in local and UAE hospitals but achieved suboptimal results. After finding information about biotherapy for diabetes, Mark's family contacted the hospital online and arrived in Beijing at the end of June.

Medical Condition before Interventional therapy and biotherapy for Diabetes:

• Congenital diabetes requiring strict dietary control and daily blood sugar monitoring
• Difficulty concentrating on studies due to his condition

Interventional therapy and biotherapy for Diabetes:
Following admission, Mark underwent relevant examinations, and a comprehensive treatment plan was implemented, consisting of:

• Interventional therapy
• Biotherapy
• Physical Therapy
• Traditional Chinese Medicine (TCM)

The entire treatment course lasted for two weeks.

Medical Condition after Interventional therapy and biotherapy for Diabetes (3 months post-treatment):

• Glycated hemoglobin: 7.5% (pre-treatment: 8.2%)
• C peptide: 0.3 (pre-treatment: < 0.1)

Mark and his family are highly satisfied with the treatment results, as he has been able to reduce the dosage of long-acting insulin. The hospital will continue to monitor Mark's progress and provide guidance on medication adjustments as needed.